Sermorelin
Research Use Only | Not for Human Consumption
A synthetic 29-amino-acid peptide corresponding to GHRH(1-29), the shortest fully active fragment of human growth hormone-releasing hormone
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-29). In preclinical research it has been examined as the minimal GHRH fragment that retains GHRH receptor binding activity comparable to the full-length 44-amino-acid peptide.
| CAS# | Formula | Molar Mass |
|---|---|---|
| 86168-78-7 | C₁₄₉H₂₄₆N₄₄O₄₂S | 3357.9 g/mol |
All products are shipped in lyophilized form and must be reconstituted for in-vitro research applications. Refer to the Certificate of Analysis for purity and identity specifications.
A synthetic 29-amino-acid peptide corresponding to GHRH(1-29); CAS 86168-78-7
What is Sermorelin?
Sermorelin emerged from research in the late 1970s and early 1980s, when scientists were working to characterize how the hypothalamus controls growth hormone release. The pivotal discovery came in 1982 when Roger Guillemin's team at the Salk Institute in California isolated and characterized the structure of growth hormone-releasing hormone from pancreatic tumors.
Researchers determined that the first 29 amino acids of the 44-amino-acid GHRH molecule retained full in vitro receptor binding activity. This truncated version, named Sermorelin (or GHRH 1-29), became a common research tool because it was easier and more economical to synthesize while preserving the receptor-binding and signaling properties observed for full-length GHRH.
Sermorelin was among the first GHRH analogs extensively studied in clinical research settings during the 1990s. Its relatively short half-life has made it useful in investigations of pulsatile GH release patterns, and it has appeared in peer-reviewed publications examining the GHRH axis across preclinical and clinical cohorts. This product is intended for research use only.
What is Sermorelin studied for?
The following research areas represent documented studies available in the scientific literature. We make no claims regarding the benefits, efficacy, or therapeutic applications of this product.
GHRH Receptor Signaling Research
In preclinical models, Sermorelin has been investigated for its interactions with pituitary GHRH receptors and downstream somatotroph signaling.
View Studies (1)GH Axis Research in Aging Cohorts
Laboratory and clinical investigations have examined Sermorelin's associations with GHRH-axis parameters across aging research cohorts.
View Studies (1)Somatotroph cAMP Research
In vitro studies have examined Sermorelin's effects on adenylyl cyclase activation and cAMP accumulation in somatotroph cell models.
View Studies (1)Pulsatile GH Release Research
Published investigations have characterized Sermorelin's role in pulsatile growth hormone release patterns in preclinical and clinical research settings.
View Studies (1)How should Sermorelin be stored?
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability.
After reconstitution, the peptides will remain stable for up to 30 days.
Certificate of Analysis
All Sermorelin batches are independently tested by a third-party laboratory for purity and identity verification via HPLC with UV detection coupled with Mass Spectrometry.
HPLC Purity
—
No Certificate of Analysis is available for the selected size yet. Contact support for batch-specific documentation.
COA documents are updated with each new batch. Contact support for batch-specific documentation.
Related Research Compounds
Frequently purchased with Sermorelin
Add all 3 items to your cart
$285
Clinical References
- Corpas E, et al. Growth hormone-releasing hormone and growth hormone secretagogues in clinical and experimental therapeutics. Hormone Research. 1993.
- Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997. PubMed: 9005976
- Steiger A, et al. Growth hormone-releasing hormone improves the quality of sleep. Experimental and Clinical Endocrinology & Diabetes. 1995.
- Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006. PubMed: 18046908
